{"id":214,"date":"2020-05-07T08:00:06","date_gmt":"2020-05-07T08:00:06","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=214"},"modified":"2020-05-19T11:46:49","modified_gmt":"2020-05-19T11:46:49","slug":"07-may-2020-lopinavir-ritonavir-no-benefit-was-observed-with-lopinavir-ritonavir-treatment-beyond-standard-care","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/07-may-2020-lopinavir-ritonavir-no-benefit-was-observed-with-lopinavir-ritonavir-treatment-beyond-standard-care\/","title":{"rendered":"(07 May 2020) Lopinavir\/Ritonavir- no benefit was observed with lopinavir\u2013ritonavir treatment beyond standard care"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\" style=\"padding-top: 0px;\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"m-article-header__title f-h18\"><span class=\"title_default\">A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19<\/span><\/p>\n<p class=\"\"><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2001282?query=featured_coronavirus\">https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2001282?query=featured_coronavirus<\/a><\/p>\n<p class=\"\">In a randomized, controlled, open-label trial of 199 patients with laboratory-confirmed SARS-CoV-2 infection; 99 were assigned to the lopinavir\u2013ritonavir group, and 100 to the standard-care group. Treatment with lopinavir\u2013ritonavir was not associated with a difference from standard care in the time to clinical improvement. <span class=\"O1056PNEJMcme2001282DONENAv11chv O1056PNEJMcme2001282DONENBv11chw \">Mortality at 28 days was similar in the lopinavir\u2013ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, \u22125.8 percentage points; 95% CI, \u221217.3 to 5.7).<\/span>&nbsp;The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir\u2013ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir\u2013ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir\u2013ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19 https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2001282?query=featured_coronavirus In a randomized, controlled, open-label trial of 199 patients with laboratory-confirmed SARS-CoV-2 infection; 99 were assigned to the lopinavir\u2013ritonavir group, and 100 to the standard-care group. Treatment with lopinavir\u2013ritonavir&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/07-may-2020-lopinavir-ritonavir-no-benefit-was-observed-with-lopinavir-ritonavir-treatment-beyond-standard-care\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(07 May 2020) Lopinavir\/Ritonavir- no benefit was observed with lopinavir\u2013ritonavir treatment beyond standard care&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,12],"tags":[41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/214"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=214"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/214\/revisions"}],"predecessor-version":[{"id":215,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/214\/revisions\/215"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}